Previous 10 | Next 10 |
-- On Track for Proof-of-Concept Results in HAE Patients in Mid-2024 -- -- Results To-Date Support STAR-0215 Administration Once Every Three or Six Months for Robust Suppression of HAE Attacks -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it has named John Ruesch as Senior Vice ...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information regarding pa...
2023-07-07 18:04:08 ET Summary Astria Therapeutics is developing STAR-0215, a monoclonal antibody inhibitor, for the treatment of hereditary angioedema (HAE), with promising initial findings and ongoing clinical trials. The company reported a Q1 2023 operating loss of $13.5 millio...
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information on STAR-0215 and i...
2023-05-11 17:19:12 ET Astria TherapeuticS press release ( NASDAQ: ATXS ): Q1 GAAP EPS of -$0.40 beats by $0.15 . As of March 31, 2023, Astria had cash, cash equivalents and short-term investments of $213.3 million, compared to $226.4 million as of December 31, 2022. T...
-- Administration of STAR-0215 to HAE Patients is Underway in the ALPHA-STAR Phase 1b/2 Trial -- -- ALPHA-STAR on Track for Initial Proof-of-Concept Results Anticipated Mid-2024 -- -- Mechanistic Modeling Data Supports STAR-0215 Administration Once Every Three or Six Months for Ro...
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information on STAR-0215 and i...
2023-04-24 08:10:36 ET Summary Proof of concept in using STAR-0215 as a preventative Hereditary Angioedema therapy had been established. Results from the phase 1b/2 ALPHA-STAR study using STAR-0215 as a preventative therapy for HAE are going to be released in mid-2024. It is e...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, announced today that it has promoted Andrea Matthews to Chief...
News, Short Squeeze, Breakout and More Instantly...
Astria Therapeutics Inc. Company Name:
ATXS Stock Symbol:
NASDAQ Market:
Astria Therapeutics Inc. Website:
2024-06-16 18:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allerg...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Va...